Propanc Biopharma (PPCB) Stock: Buy, Sell, or Hold?
PPCB - Propanc Biopharma, Inc. Common Stock
$0.28
0.01 (2.19%)
▲
5d:
-18.13%
30d:
-53.47%
90d:
-78.79%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 13, 2026
19d
Get Alerted When PPCB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PPCB is down 18.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PPCB is down 18.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PPCB is currently trading at $0.28, which is considered oversold relative to its 30-day fair value range of $0.36 to $0.62.
Technical Outlook: Technically, PPCB is in a strong downtrend. Immediate support is located at $0.25, while resistance sits at $0.49.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.52 (+442.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PPCB is in a strong downtrend. Immediate support is located at $0.25, while resistance sits at $0.49.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.52 (+442.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.36 -
$0.62
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 442.9% below Wall St target ($1.52)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.36 -
$0.62
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.25
Resistance Level
$0.49
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Wall Street Target
$1.52
(+442.9%)
Share & Embed Analysis
Last updated: October 24, 2026 9:10 AM ET
Data refreshes hourly during market hours. Next update: 10:10 AM
Data refreshes hourly during market hours. Next update: 10:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PPCB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |